Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 202 UK small molecule drug companies below.
Integrated chemistry and development CRO for small molecules
CatSci is a Cardiff-headquartered contract research organisation providing integrated chemistry, analytical, and development services to biotech and pharmaceutical companies.…
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline…
API development and manufacturing for pharmaceutical drug substances
Aptuit is a pharmaceutical chemical development and manufacturing site operating as part of Evotec's API and drug product network. The company develops and manufactures active…
Clinical-stage oncology company advancing in-licensed cancer drug assets
Ellipses Pharma is a clinical-stage oncology drug development company that in-licenses cancer drug assets from academia and industry, advances them through clinical trials using a…
Clinical-stage precision oncology developing first-in-class TACC3 inhibitor therapeutics
Coiled Therapeutics is a UK-listed, clinical-stage oncology company developing precision cancer therapeutics against structurally complex, previously undruggable targets. Its lead…
Integrated contract drug discovery from Cambridge and India
o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology,…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments…
Personalised cancer treatment selection using in vivo drug screening
Vivan Therapeutics is a London-based biotech developing a personalised cancer therapeutics platform. The company's Personal Discovery Process sequences a patient's tumour genome,…
Phase III-ready antimicrobial advancing post-surgical infection prevention
AMR Bio is a clinical-phase biotechnology company advancing XF-73, a Phase III-ready topical antimicrobial using an ultra-rapid antibacterial mechanism to prevent post-surgical…
Targeted oncology combination therapies in biomarker-defined cancer populations
Mosaic Therapeutics is a Cambridge biotech developing targeted combination therapies for cancer. Its proprietary platform integrates genome-scale CRISPR screening, high-throughput…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The…